Literature DB >> 3543636

Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol.

A J Felsenfeld, R A Gutman, M Drezner, F Llach.   

Abstract

The effects of long-term hypophosphatemia were studied in 10 renal transplant recipients with persistent hypophosphatemia. The renal transplant recipients are 3-14 years (mean 8.7 +/- 4 years) post transplantation. The mean (+/- SD) serum calcium, phosphate, and creatinine levels are 9.66 +/- 0.42, 2.29 +/- 0.16, and 1.47 +/- 0.23 mg/dl, respectively. Carboxy (C)-terminal parathyroid hormone (PTH) is elevated in 8 hypophosphatemic renal transplant recipients. The mean 1,25-dihydroxycholecalciferol [1,25(OH)2D3] level is 33 +/- 20 pg/ml (normal 19-55 pg/ml) compared to 42 +/- 0.6 pg/ml (NS) in 4 normophosphatemic renal transplant recipients with comparable renal function. The 1,25(OH)2D3 level correlates with C-PTH (p less than 0.01) but not serum phosphate. Anterior iliac crest bone biopsies were obtained in all 10 hypophosphatemic renal transplant recipients. Histomorphometric analysis of osteoblastic osteoid, total surface osteoid, bone-osteoclast interface, total resorption, osteoclasts/mm2, osteoid seam width, and relative osteoid volume are not significantly different from normals. Trabecular bone volume is decreased (15.6 +/- 5.7 vs. 23 +/- 5%, p less than 0.01). Comparison of dynamic parameters with normal reveals no differences in appositional and bone formation rate. In summary, in hypophosphatemic renal transplant recipients: hypophosphatemia does not produce osteomalacia; hyperparathyroidism is often observed, and plasma 1,25(OH)2D3 levels, in general, remain in the normal range.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3543636

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  7 in total

Review 1.  Management of mineral and bone disorder after kidney transplantation.

Authors:  Kamyar Kalantar-Zadeh; Miklos Z Molnar; Csaba P Kovesdy; Istvan Mucsi; Suphamai Bunnapradist
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

2.  Renal phosphate loss in long-term kidney transplantation.

Authors:  Supinda Sirilak; Kamonwan Chatsrisak; Atiporn Ingsathit; Surasak Kantachuvesiri; Vasant Sumethkul; Wasana Stitchantrakul; Piyanuch Radinahamed; Sinee Disthabanchong
Journal:  Clin J Am Soc Nephrol       Date:  2011-12-01       Impact factor: 8.237

3.  Post-Transplant Hypophosphatemia and the Risk of Death-Censored Graft Failure and Mortality after Kidney Transplantation.

Authors:  Marco van Londen; Brigitte M Aarts; Petronella E Deetman; Jessica van der Weijden; Michele F Eisenga; Gerjan Navis; Stephan J L Bakker; Martin H de Borst
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-25       Impact factor: 8.237

Review 4.  Post-renal transplantation hypophosphatemia.

Authors:  Khashayar Sakhaee
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

Review 5.  Phosphate and FGF-23 homeostasis after kidney transplantation.

Authors:  Leandro C Baia; Ita Pfeferman Heilberg; Gerjan Navis; Martin H de Borst
Journal:  Nat Rev Nephrol       Date:  2015-09-29       Impact factor: 28.314

Review 6.  New Therapies for Hypophosphatemia-Related to FGF23 Excess.

Authors:  Diana Athonvarangkul; Karl L Insogna
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

Review 7.  Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.

Authors:  Sophie Liabeuf; Lynda Cheddani; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2018-06-05       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.